Here, we show the combination of the PI3K inhibitor ZSTK474 and anti-PD-1 mAb as a novel cancer immunotherapy to achieve decreased Treg function and augmented effector T cell function with an optimized protocol. The gene discussed is PDCD1; the disease is cancer.